Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Kaubisch

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2014
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine TumorsTimothy J Hobday, Rui Qin, Diane Reidy-Lagunes, et al.
Investigational New Drugs|October 17, 2014
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinomaJennifer J Knox, Rui Qin, Jonathan R Strosberg, et al.
Clinical Colorectal Cancer|April 17, 2017
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal CancerSanjay Goel, Abdissa Negassa, Ashish Khot, et al.
JAMA Network Open|November 5, 2020
Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular CarcinomaKeara English, N Patrik Brodin, Viswanathan Shankar, et al.
The Journal of Clinical Investigation|July 13, 2011
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and miceHongwei Wang, Madhukumar Venkatesh, Hao Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumorsJeremy Kortmansky, Manish A Shah, Andreas Kaubisch, et al.
Journal of Hepatocellular Carcinoma|February 9, 2024
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United StatesFernand Bteich, Kush Desai, Chenxin Zhang, et al.
Oncotarget|October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatinDevika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Endocrine-Related Cancer|September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumorsSonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
American Journal of Clinical Oncology|May 8, 2013
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II studyHoward Safran, Kevin P Charpentier, Andreas Kaubisch, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2014
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine TumorsTimothy J Hobday, Rui Qin, Diane Reidy-Lagunes, et al.
Investigational New Drugs|October 17, 2014
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinomaJennifer J Knox, Rui Qin, Jonathan R Strosberg, et al.
Clinical Colorectal Cancer|April 17, 2017
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal CancerSanjay Goel, Abdissa Negassa, Ashish Khot, et al.
JAMA Network Open|November 5, 2020
Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular CarcinomaKeara English, N Patrik Brodin, Viswanathan Shankar, et al.
The Journal of Clinical Investigation|July 13, 2011
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and miceHongwei Wang, Madhukumar Venkatesh, Hao Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumorsJeremy Kortmansky, Manish A Shah, Andreas Kaubisch, et al.
Journal of Hepatocellular Carcinoma|February 9, 2024
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United StatesFernand Bteich, Kush Desai, Chenxin Zhang, et al.
Oncotarget|October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatinDevika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Endocrine-Related Cancer|September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumorsSonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
American Journal of Clinical Oncology|May 8, 2013
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II studyHoward Safran, Kevin P Charpentier, Andreas Kaubisch, et al.
Pageof 4